Objectives: The study aimed to evaluate clinical and paraclinical characteristics of left atrial myxoma and the early result of minimally invasive left atrial myxoma resection at E hospital. Patients and methods: This is retrospective, descriptive study of consecutive patients, who underwent minimally invasive left atrial myxoma rejection, using total or video-assisted endoscopic technique from October 2016 to March 2021 at E hospital. There were 31 patients, consisting of 27 females and 04 males. The mean age was 53 ± 13 years old (range [17-74]). Results: Preoperative clinical manifestations were diverse. Asymptomatic form was in 3 patients (9.7%), hemodynamic symptoms were in 26 patients (83.9%), embolism were presented in 4 patients (12.9%), systemic symptoms were in 8 patients (25.8%). Anemia and elevated erythrocyte sedimentation rates were observed in 45.2% and 74.2%, respectively. Echocardiography results: the average tumor size was 4.2 ± 1.7 cm (range [1.7-8]), the site of attachment was mainly in the atrial septum (77.4%). Cardiopulmonary bypass time was 158 ± 43 minutes (range [100-252]), cross-clamp time was 84 ± 34.2 minutes (range [42-153]), ventilation time was 10,8 ± 7,0 hours (range [3-30]), intensive care unit stay was 1,5 ± 1,0 days (range [0.5-4]), and in-hospital stay was 9.5 ± 5.0 days (range [3-30]). There was no hospital mortality. Cerebrovascular accident was presented in one (3.2%), femoral artery stenosis was in one (3.2%), atrial fibrillation after surgery was in one(3.2%).There was no bleeding, that require reoperation, and no other serious complications. Conclusions: Initial results of left atrial myxoma resection, using minimally invasive total or video-assisted technique wassafe and effectivewith low complications, could be recommended toapply routinely in cardiac surgery centers.
Objectives: The study aimed to evaluate clinical and paraclinical characteristics of left atrial myxoma and the early result of the minimally invasive procedure to remove left atrial myxoma at E hospital. Subjects and methods: This is retrospective, descriptive study of consecutive patients, who underwent minimally invasive left atrial myxoma rejection, using total or video-assisted endoscopic technique from October 2016 to March 2021 at E hospital. There were 31 patients, consisting of 27 females and 04 males. The mean age was 53 ± 13 years old (from 17 to 74 years old) Results: Preoperative clinical manifestations were diverse. Asymptomatic form was in 3 patients (9.7%), hemodynamic symptoms were in 26 patients (83.9%), embolism symptoms were presented in 4 patients (12.9%), systemic symptoms (25.8. Anemia and elevated erythrocyte sedimentation rates were observed in 45.2% and 74.2%, respectively. Echocardiography results: the average tumor size was 4,8 ± 1,8 cm (from 1.7 to 8 cm), the site of attachment was mainly in the atrial septum (77.4%). Cardiopulmonary bypass time was 158 ± 43 minutes (from 100 to 252 minutes), cross-clamp time was 84 ± 34 minutes (from 42 to 153 minutes). Ventilation time was 10,8 ± 7,0 hours (from 3 to 30 hours), intensive care unit stay was 1,5 ± 1,0 days (from 0.5 to 4 days), and in-hospital stay was 9.5 ± 5.0 days (from 3 to 30 days). There was no hospital mortality. Cerebrovascular accident was presented in one (3.2%), femoral artery stenosis was in one (3.2%), atrial fibrillation after surgery was in one (3.2%). There was no bleeding, that require reoperation, and no other serious complications. Conclusions: Initial results of left atrial myxoma rejection, using minimally invasive total or video-assisted technique wassafe and effectivewith low complications, could be recommended to apply routinely in cardiac surgery centers
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.